Skip to content
Baltimore News Journal – Lifestyle
Author:
Oricell Therapeutics Co., Ltd.
OriCell’s GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
June 7, 2026
ASCO 2026 | Oricell’s GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
May 31, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
April 9, 2026